HbA1c
[HbA1c]
EPTIS Ringversuch Nr. 142535 | Letze Änderung 2024-09-24 | URL: https://www.eptis.bam.de/pts142535 https://www.eptis.bam.de/pts142535
| Name des Anbieters | |||||||
| Name des Anbieters | Weqas Weqas | ||||||
| Ansässig in | United Kingdom | ||||||
| Sprache(n) | |||||||
| Anmerkungen | HbA1c is used for both the diagnosis (Type 2) and monitoring of diabetes (Type 1 & 2) as an initial screen to identify having a risk of developing diabetes. The programme aim is to cover the clinically relevant ranges, encompassing the diagnostic cut-off level, of 48mmol/mol Hb for the diagnosis of diabetes. However, the analytical measuring range will also be assessed where appropriate. Fresh EDTA whole blood from individual diabetic patients and healthy volunteers are distributed monthly/bi-monthly. These samples reflect the wide range of HbA1c seen in healthy individuals and in Diabetic patients. Challenging samples from patients with known Hb variants are also distributed to assess current practice. Samples from volunteers and diabetic patients are distributed to ensure that the concentration range is appropriate for population health check screening, diabetes diagnosis and diabetes patient monitoring. Key Features: - Whole blood samples are collected from healthy volunteers and patients with Type II Diabetes. - Samples cover non-diabetic, diagnostic cut-off level, (48mmol/mol Hb), pathological and analytical ranges. - Case studies including challenging samples with known Hb variants distributed to assess current laboratory practice. - Sigma metric scoring based on clinically relevant Milan Model 1 performance specification. - Programme assesses both laboratory and method performance, including trueness, bias, within and between batch imprecision. - Trueness is assessed using the IFCC secondary reference methods with Sigma metric scoring based on clinically relevant Milan Model 1 performance specification. - Additional samples are distributed annually as part of the European HbA1c Trial to assess the performance across all countries and all manufacturers. The full report is provided as part of the programme. For more information: https://www.weqas.com/services/eqa/hba1c/ or contact@weqas.com | ||||||
| Klassifizierung | |||||||
| Produktgruppen |
Health care / medical devices
|
||||||
| Prüfgebiete |
Medical analysis
|
||||||
| Technische Einzelheiten | |||||||
|
|||||||
| Ringversuchsziele | |||||||
| Zielgruppe des Ringversuchs | The programme is suitable for all Laboratory and POCT applications. | ||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS based on ISO/IEC 17043. | ||||||
| Weitere Ziele | validation of testing methods | ||||||
| Teilnehmerzahl | |||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 |
||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | |||||||
| Kosten | |||||||
| Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | ||||||
| Regelmässig durchgeführt | Ja (Frequency: Monthly / Bimonthly. Samples: 3 x 0.2mL / 2 x 0.2mL (2 samples in bimonthly programme)) | ||||||
| Der Ringversuch wird durchgeführt seit | 1996 | ||||||
| Kontaktdaten des Anbieters | |||||||
| Anbieter | Kontaktperson | ||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.